Tajuk : One of the most hated drug companies on Wall Street is facing another nasty probe
link : One of the most hated drug companies on Wall Street is facing another nasty probe
One of the most hated drug companies on Wall Street is facing another nasty probe
J. Scott Applewhite/AP
Sen. Claire McCaskill (D-MO)
Senator Claire McCaskill (D-MO) has sent a letter to Mallinckrodt Pharmaceuticals, asking the company for details about the pricing of its pain medication, Ofirmev.
Ofirmev can be used as a safer alternative to opioids, and Mallinckrodt acquired the drug in 2014 when it purchased Cadence Pharmaceuticals for $1.4 billion.
Almost immediately after the sale, Mallinckrodt doubled the price of Ofirmev to 1,019.52 for a pack of 24 vials.
This is costing hospitals a fortune, so some of them are using cheaper more dangerous painkillers — highly addictive opioids. So, Senator McCaskill, who is also investigating a number of opioid manufacturers, is looking into the impact Ofirmev’s price increase has had on “hospital decision making.”
Mallinckrodt has yet to respond to our request for comment.
Notorious MNK
Markets Insider
Mallinckrodt has gained notoriety on Wall Street over this year, but not for Ofirmev. Instead, it is because of its blockbuster drug, Acthar. That’s another old drug that has seen its price skyrocket as it was sold from one drug company to the next.
Earlier this month at a conference in Las Vegas, famed short seller Jim Chanos presented his case that Mallinckrodt’s revenue relies too heavily on Acthar sales, despite the fact that it’s a drug with questionable efficacy for many of the ailments it is prescribed for.
He’s not the first on Wall Street to make that point either. Andrew Left of Citron Research has been challenging the company to test Acthar, which is primarily used to treat infantile spasms.
What makes Acthar so strange, is that most of its revenue comes from Medicare, which is a program for the elderly — a point that hasn’t escaped the short selling community. We should also note that former Turing CEO Martin Shkreli, a man who became public enemy number one after jacking up the price of a life-saving AIDs treatment, also took issue with Mallinckrodt.
In 2014, he complained to the feds — specifically the Federal Trade Commission — about a drug company’s anticompetitive behavior. It later settled that matter for $100 million.
Currently, the Department of Justice, the SEC and other US attorneys are all investigating the company.
So you can see why the last thing the company needs is Senator McCaskill asking for documents.
You can read her full letter below.
2017-05-18 CMC to Mallinckrodt Re Ofirmev by Linette Lopez on Scribd
Read more stories on Business Insider, Malaysian edition of the world’s fastest-growing business and technology news website.
✍ Sumber Pautan : ☕ Business InsiderBusiness Insider
Kredit kepada pemilik laman asal dan sekira berminat untuk meneruskan bacaan sila klik link atau copy paste ke web server : http://ift.tt/2s4RZfP
(✿◠‿◠)✌ Mukah Pages : Pautan Viral Media Sensasi Tanpa Henti. Memuat-naik beraneka jenis artikel menarik setiap detik tanpa henti dari pelbagai sumber. Selamat membaca dan jangan lupa untuk 👍 Like & 💕 Share di media sosial anda!
Thus Article One of the most hated drug companies on Wall Street is facing another nasty probe
Anda sedang baca artikel One of the most hated drug companies on Wall Street is facing another nasty probe dengan alamat pautan https://malaysiaonrecord.blogspot.com/2017/05/one-of-most-hated-drug-companies-on.html
Related Posts :
Kisah Pertukaran Kiblat Dari Baitulmuqaddis ke Kota Suci Mekah- 'Dah meninggal, apsal tak inform awal?' - Kepala bana punya customer, kata netizen
- Apple’s HomePod is not artificial intelligence — but it is a great speaker
- Jari tangan dan alat sulit digigit babi, petani maut
- Jabatan Penjara Malaysia tetapkan tarikh 27 dan 28 Jun untuk lawatan Aidilfitri
0 Response to "One of the most hated drug companies on Wall Street is facing another nasty probe"
Catat Ulasan